Fed. Circ. Blocks Generic Sales Of AstraZeneca's Pulmicort

Law360, New York (May 28, 2013, 12:41 PM EDT) -- The Federal Circuit on Friday blocked four generic-drug makers from launching no-name versions of AstraZeneca PLC's Pulmicort Respules pediatric asthma medication while the pharmaceutical giant appeals a lower court ruling in New Jersey that one of its patents is invalid and the other hasn't been infringed.

A three-judge panel said AstraZeneca showed that it was entitled to an injunction against Apotex Inc.,  Breath Ltd, Sandoz Inc. and Actavis Inc. during the course of its appeal and ordered AstraZeneca to post a $72 million bond within seven...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.